FDA Discusses Drug Traceability Implementation with Pharma Companies
- The Food and Drug Governance (FDA) is currently engaged in discussions with pharmaceutical companies and third-party manufacturing stores regarding the practical implementation of a drug traceability project.
- The meetings center on establishing a clear mechanism for tracking and tracing prescription drugs throughout the supply chain.
- The DSCSA mandates a phased approach to drug traceability, with full implementation scheduled for October 19, 2025.
FDA Discusses Drug Traceability Implementation with Industry
Table of Contents
Drug Supply Chain Security Act Implementation
The Food and Drug Governance (FDA) is currently engaged in discussions with pharmaceutical companies and third-party manufacturing stores regarding the practical implementation of a drug traceability project. This initiative stems from the Drug Supply Chain Security Act (DSCSA), aimed at enhancing the security of the pharmaceutical supply chain and protecting patients from counterfeit drugs.
Focus of Discussions
The meetings center on establishing a clear mechanism for tracking and tracing prescription drugs throughout the supply chain. Details of the implementation plan are being refined through these collaborative sessions, ensuring feasibility and effectiveness for all stakeholders. The FDA seeks to address potential challenges and ensure a smooth transition to the new traceability requirements.
DSCSA Requirements
The DSCSA mandates a phased approach to drug traceability, with full implementation scheduled for . this includes requirements for serialization, verification, and data exchange at each stage of the supply chain, from manufacturer to dispenser. The goal is to create an electronic, interoperable system for tracking prescription drugs.